SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

TNGX

Tango Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed7d 17h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The vopimetostat data and regulatory engagement plans are the primary value drivers. Monitor FDA feedback on accelerated approval path and Phase 3 initiation in 1H 2027. The cash runway appears sufficient through key milestones. The G&A spike from equity modifications is non-recurring but the R&D burn rate is rising.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

ERAS-0015

◆ Mixed Named in this press release
Impact
Phase
Phase 1
Time to market
~3-5 years, assuming registration-enabling trials initiate in 2027 and a potential approval by ~2029-2030
Next catalyst
None dated

What to watchERAS-0015 Phase 1 data is genuinely strong (57-62% response rates in difficult-to-treat tumors) but the stock carries heavy legal baggage, a securities class action and patent-infringement allegations from Revolution Medicines. The stock recovered from its April 48% crash to ~$18; watch for the August 10, 2026 lead-plaintiff deadline and any developments in the Revolution Medicines patent dispute, which could swing shares sharply. The registration-enabling trial initiations in H1 2027 are the next major de-risking catalyst.

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$22.74
T+0 close · Nov 9, 2026 · via day close
Latest settled
+6.29%
T+5 · $24.17
Vs SPY
+7.98%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $22.74entry
  2. T+1 · 7d ago +6.86%α +7.23% · $24.30
  3. T+5 · 17h ago +6.29%α +7.98% · $24.17
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tango Therapeutics reported Q3 2026 net loss of $68.4M ($0.39/share) vs net income of $15.9M ($0.14/share) in Q3 2025, driven by higher R&D and G&A expenses and the end of Gilead collaboration revenue. Cash stood at $977.5M. The key catalyst was promising Phase 1/2 data for vopimetostat plus daraxonrasib in pancreatic cancer (82% ORR, 88% 9-month PFS), with plans for a Phase 3 registrational study in 1H 2027 and potential accelerated approval discussions.

Key Financial Metrics

EPS
−$0.39
Revenue
$0.00
est $0.00 · -100.0% YoY

Key Facts

  • Net loss Q3 2026: $68.4M ($0.39/share) vs net income $15.9M ($0.14/share) in Q3 2025
  • Cash, cash equivalents and marketable securities: $977.5M as of Sep 30, 2026
  • Collaboration revenue: $0 in Q3 2026 vs $53.8M in Q3 2025 (Gilead deal ended)
  • R&D expenses: $48.9M in Q3 2026 vs $30.8M in Q3 2025
  • G&A expenses: $29.2M in Q3 2026 vs $8.9M in Q3 2025 (includes equity award modifications for former executives)
  • Phase 1/2 data for vopimetostat + daraxonrasib: 82% ORR, 88% 9-month PFS in 2L/3L pancreatic cancer
  • Registrational Phase 3 study planned in front-line MTAP-deleted pancreatic cancer in 1H 2027
  • Company plans to discuss accelerated approval in 2L pancreatic cancer with regulators
  • Strategic reprioritization to focus on PRMT5-targeted therapies

Financial Impact

Net loss widened by $84.3M YoY; cash burn rate increased; no revenue in the quarter

net incomerevenueoperating expensescash position

Risk Factors

  • No current revenue; fully dependent on pipeline success
  • Phase 3 trial may fail to replicate Phase 1/2 results
  • Regulatory path for accelerated approval uncertain
  • Rising R&D and G&A expenses increase cash burn
  • Competition from other PRMT5 and RAS-targeted therapies

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398261

Track record

27 reports on TNGX

Performance horizon

3 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +29.28% at T+60 after the Jun 8, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.22 Now $24.17 +0.21% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.50 Now $24.17 +1.35% settles Feb 12
  3. Nov 9, 20267d ago Press Release Neutral 5/10 Viewing Entry $22.74 Now $24.17 +6.29% settles Feb 5
  4. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $21.50 Now $24.17 +12.42% settles Feb 4
  5. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $20.87 Now $24.17 +15.81% settles Feb 3
  6. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
  7. Nov 2, 202614d ago 144 Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
  8. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $23.34 Now $24.17 +3.56% settles Jan 21
  9. Aug 11, 202613w ago 8-K Bearish 6/10 Entry $25.58 to $23.18 Now $24.17 +5.51% ▲ +9.38% +4.51% vs SPY
  10. Aug 11, 202613w ago 8-K Bullish 7/10 No price data
Showing 10 of 27

US Market Status

Market Closed · Opens in 9h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026